vTv Therapeutics Inc. (VTVT): Total Assets
$89.90M
As of 2025-12-31
$87.59M
As of 2026-06-30
+39.3%
3-year compound annual growth
+43.5%
5-year compound annual growth
-0.2%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $89.90M | +134.9% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $38.27M | +247.3% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $11.02M | -66.9% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $33.24M | +30.5% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $25.47M | +72.2% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $14.79M | +59.6% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $9.27M | +8.3% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $8.56M | -69.3% | 2020-02-21, Balance as of period end |
| 2017-12-31 | $27.92M | -48.8% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $54.49M | -40.5% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $91.53M | +606.8% | 2017-02-24, Balance as of period end |
| 2014-12-31 | $12.95M | n/a | 2016-03-04, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $89.90M | +134.9% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare VTVT, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗